CY1115582T1 - Νεα πρωτεϊνη υποδοχεα αιμοποιητινης, nr10 - Google Patents

Νεα πρωτεϊνη υποδοχεα αιμοποιητινης, nr10

Info

Publication number
CY1115582T1
CY1115582T1 CY20141100484T CY141100484T CY1115582T1 CY 1115582 T1 CY1115582 T1 CY 1115582T1 CY 20141100484 T CY20141100484 T CY 20141100484T CY 141100484 T CY141100484 T CY 141100484T CY 1115582 T1 CY1115582 T1 CY 1115582T1
Authority
CY
Cyprus
Prior art keywords
novel
receptor
hemopoietin
receptors
hematopoietic
Prior art date
Application number
CY20141100484T
Other languages
English (en)
Inventor
Masatsugu Maeda
Noriko Yaguchi
Original Assignee
Chugai Seiyaku Kabushiki Kaisha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26483716&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1115582(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Seiyaku Kabushiki Kaisha filed Critical Chugai Seiyaku Kabushiki Kaisha
Publication of CY1115582T1 publication Critical patent/CY1115582T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Οι εφευρέτες πέτυχαν την απομόνωση ενός νέου γονίδιου υποδοχέα αιμοποιητίνης (NR10), χρησιμοποιώντας μια ακολουθία που προβλέπεται από το μοτίβο που έχει εξαχθεί και διατηρείται στις ακολουθίες αμινοξέων γνωστών υποδοχέων αιμοποιητίνης. Αναμένονταν ότι θα υπάρχουν δύο μορφές της NR10, μια διαμεμβράνιου τύπου και μια διαλυτή μορφή. Η έκφραση του προηγούμενου τύπου ανιχνεύθηκε στους ιστούς που περιέχουν τα αιμοποιητικά κύτταρα. Επομένως, η NR10 είναι ένα νέο μόριο υποδοχέα αιμοποιητίνης που εμπλέκεται στη ρύθμιση του ανοσοποιητικού συστήματος ή στην αιμοποίηση in vivo. Οι νέοι αυτοί υποδοχείς είναι χρήσιμοι στη διαδικασία διαλογής για νέους αιμοποιητικούς παράγοντες που έχουν την ικανότητα να δεσμεύονται λειτουργικά στον υποδοχέα ή στην ανάπτυξη φαρμάκων για την αντιμετώπιση ασθενειών σχετικών με το ανοσοποιητικό σύστημα ή το αιμοποιητικό σύστημα.
CY20141100484T 1999-06-02 2014-07-01 Νεα πρωτεϊνη υποδοχεα αιμοποιητινης, nr10 CY1115582T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP15579799 1999-06-02
JP21779799 1999-07-30
EP09012659.0A EP2135953B1 (en) 1999-06-02 2000-06-01 Novel hemopoietin receptor protein, Nr. 10

Publications (1)

Publication Number Publication Date
CY1115582T1 true CY1115582T1 (el) 2017-01-04

Family

ID=26483716

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100484T CY1115582T1 (el) 1999-06-02 2014-07-01 Νεα πρωτεϊνη υποδοχεα αιμοποιητινης, nr10

Country Status (11)

Country Link
US (6) US7482440B2 (el)
EP (3) EP2325316B8 (el)
JP (7) JP2007111051A (el)
AT (1) ATE455852T1 (el)
AU (1) AU4952400A (el)
CY (1) CY1115582T1 (el)
DE (1) DE60043728D1 (el)
DK (1) DK1188830T3 (el)
ES (1) ES2339843T3 (el)
PT (1) PT1188830E (el)
WO (1) WO2000075314A1 (el)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2325316B8 (en) 1999-06-02 2017-04-19 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor protein, NR10
EP1221482B1 (en) * 1999-09-27 2005-12-28 Chugai Seiyaku Kabushiki Kaisha Hemopoietin receptor protein, nr12
DK1325115T3 (en) * 2000-06-26 2016-11-21 Zymogenetics Inc CYTOKINRECEPTOR ZCYTOR17
US20030096339A1 (en) 2000-06-26 2003-05-22 Sprecher Cindy A. Cytokine receptor zcytor17
US7317075B2 (en) * 2000-07-20 2008-01-08 Genentech, Inc. PRO21384 polypeptides
US20030059871A1 (en) * 2000-10-06 2003-03-27 Cosman David J. Hematopoietin receptors HPR1 and HPR2
WO2002077230A1 (fr) * 2001-03-26 2002-10-03 Chugai Seiyaku Kabushiki Kaisha Variants d'epissage nr10
EP2338910B1 (en) 2002-01-18 2015-07-08 ZymoGenetics, Inc. Cytokine receptor Zcytor17 multimers
EP1961811B1 (en) 2002-01-18 2010-08-25 ZymoGenetics, Inc. Cytokine ligand for the treatment of asthma and airway hyper-responsiveness
US9738700B2 (en) 2002-01-18 2017-08-22 Zymogenetics Inc. ZCYTOR17 heterodimeric cytokine receptor
US20050255545A1 (en) * 2002-02-01 2005-11-17 Smith Timothy J Regulation of human hematopoietin receptor-like protein
CA2477249A1 (en) * 2002-02-25 2003-09-04 Genentech, Inc. Novel type-1 cytokine receptor glm-r
MX2007009718A (es) 2005-02-14 2007-09-26 Zymogenetics Inc Metodos para tratar trastornos cutaneos utilizando un antagonista il-31ra.
US8101183B2 (en) 2005-05-06 2012-01-24 Zymogentics, Inc. Variable region sequences of IL-31 monoclonal antibodies
US20130216542A1 (en) 2005-05-06 2013-08-22 Zymogenetics, Inc. Variable region sequences of il-31 monoclonal antibodies and methods of use
EP2301969B1 (en) 2005-05-06 2015-12-23 ZymoGenetics, Inc. IL-31 monoclonal antibodies and methods of use
EP2001906A2 (en) 2006-01-10 2008-12-17 Zymogenetics, Inc. Methods of treating pain and inflammation in neuronal tissue using il-31ra and osmrb antagonists
DK3056568T3 (da) 2006-03-31 2021-11-01 Chugai Pharmaceutical Co Ltd Fremgangsmåder til kontrollering af antistoffers blodfarmakokinetik
PE20080333A1 (es) * 2006-06-08 2008-06-15 Chugai Pharmaceutical Co Ltd Agentes para prevenir o tratar enfermedades inflamatorias
JP5334319B2 (ja) 2007-09-26 2013-11-06 中外製薬株式会社 Ｃｄｒのアミノ酸置換により抗体の等電点を改変する方法
SG193868A1 (en) 2007-09-26 2013-10-30 Chugai Pharmaceutical Co Ltd Modified antibody constant region
CN101939424B (zh) 2007-12-05 2016-12-28 中外制药株式会社 抗nr10抗体及其应用
RU2596397C2 (ru) 2007-12-05 2016-09-10 Чугаи Сейяку Кабусики Кайся Терапевтическое средство от зуда
ES2660036T3 (es) 2007-12-07 2018-03-20 Zymogenetics, Inc. Moléculas de anticuerpo humanizadas específicas para IL-31
EP3521311A1 (en) 2008-04-11 2019-08-07 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
CN102257635A (zh) * 2008-10-23 2011-11-23 奥塔装置公司 光伏器件的薄吸收层
JP5139517B2 (ja) * 2008-12-05 2013-02-06 中外製薬株式会社 抗ｎｒ１０抗体、およびその利用
KR20160062207A (ko) * 2008-12-05 2016-06-01 추가이 세이야쿠 가부시키가이샤 항ｎｒ１０ 항체 및 그의 이용
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
EP2409991B1 (en) 2009-03-19 2017-05-03 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
TWI544077B (zh) 2009-03-19 2016-08-01 Chugai Pharmaceutical Co Ltd Antibody constant region change body
RU2642318C2 (ru) 2010-11-30 2018-01-24 Чугаи Сейяку Кабусики Кайся Антигенсвязывающая молекула, способная многократно связываться с множеством антигенных молекул
RU2749512C2 (ru) 2015-04-14 2021-06-11 Чугаи Сейяку Кабусики Кайся Фармацевтическая композиция для профилактики и/или лечения атопического дерматита, включающая антагонист ил-31 в качестве активного ингредиента
AU2019219608A1 (en) 2018-02-09 2020-08-27 Chugai Seiyaku Kabushiki Kaisha Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation
US11236157B2 (en) 2019-01-28 2022-02-01 Galderma Holding SA Treatment of skin lesions and pruritus in prurigo nodularis patients
CA3156713A1 (en) 2019-11-20 2021-05-27 Daisuke Kameoka Antibody-containing preparation
US20230391878A1 (en) 2020-09-01 2023-12-07 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for prevention and/or treatment of dialysis pruritus containing il-31 antagonist as active ingredient
TW202304510A (zh) 2021-04-07 2023-02-01 瑞士商葛德瑪控股公司 結節性癢疹之治療
AU2022337073A1 (en) 2021-08-30 2024-04-11 Chugai Seiyaku Kabushiki Kaisha Treatments for atopic dermatitis
WO2024047497A1 (en) 2022-09-02 2024-03-07 Galderma Holding SA Treatments for prurigo nodularis

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0239102A3 (en) 1986-03-28 1989-07-12 Tsuji, Kimiyoshi Process for the formation of human-human hybridoma
JP2898064B2 (ja) * 1989-08-03 1999-05-31 忠三 岸本 ヒトｇｐ１３０蛋白質
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9016440D0 (en) 1990-07-26 1990-09-12 Elopak Systems A laminate
EP0546073B1 (en) 1990-08-29 1997-09-10 GenPharm International, Inc. production and use of transgenic non-human animals capable of producing heterologous antibodies
WO1993002227A1 (en) 1991-07-15 1993-02-04 Eco-Tec Limited Process and apparatus for treating fluoride containing acid solutions
JPH07509137A (ja) 1992-07-24 1995-10-12 セル　ジェネシス，インク． 異種抗体の生産
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5783672A (en) * 1994-05-26 1998-07-21 Immunex Corporation Receptor for oncostatin M
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
AUPN481295A0 (en) 1995-08-16 1995-09-07 Medvet Science Pty. Ltd. Agonists of haemopoietic growth factors
AUPN564195A0 (en) * 1995-09-26 1995-10-19 Walter And Eliza Hall Institute Of Medical Research, The A novel haemopoietin receptor and genetic sequences encoding same
CA2238080C (en) * 1995-10-23 2012-03-13 Amrad Operations Pty. Ltd. A novel haemopoietin receptor and genetic sequences encoding same
US6642360B2 (en) * 1997-12-03 2003-11-04 Genentech, Inc. Secreted polypeptides that stimulate release of proteoglycans from cartilage
US6747137B1 (en) * 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
CA2330547A1 (en) 1998-06-24 1999-12-29 Chugai Research Institute For Molecular Medicine, Inc. Novel hemopoietin receptor proteins
DE60041697D1 (de) 1999-06-01 2009-04-16 Schering Corp Säugetier-rezeptorproteine; ähnliche reagentien und methoden
US20030082734A1 (en) 1999-06-01 2003-05-01 Dowling Lynette M. Mammalian receptor proteins; related reagents and methods
EP2325316B8 (en) 1999-06-02 2017-04-19 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor protein, NR10
EP1221482B1 (en) 1999-09-27 2005-12-28 Chugai Seiyaku Kabushiki Kaisha Hemopoietin receptor protein, nr12
CZ304022B6 (cs) 2000-05-10 2013-08-28 Merck Sharp & Dohme Corp. Savcí receptorové proteiny, cinidla a metody, které se jich týkají
DK1325115T3 (en) 2000-06-26 2016-11-21 Zymogenetics Inc CYTOKINRECEPTOR ZCYTOR17
US20030059871A1 (en) 2000-10-06 2003-03-27 Cosman David J. Hematopoietin receptors HPR1 and HPR2
WO2002077230A1 (fr) 2001-03-26 2002-10-03 Chugai Seiyaku Kabushiki Kaisha Variants d'epissage nr10
EP2338910B1 (en) 2002-01-18 2015-07-08 ZymoGenetics, Inc. Cytokine receptor Zcytor17 multimers
EP1961811B1 (en) 2002-01-18 2010-08-25 ZymoGenetics, Inc. Cytokine ligand for the treatment of asthma and airway hyper-responsiveness
CA2477249A1 (en) 2002-02-25 2003-09-04 Genentech, Inc. Novel type-1 cytokine receptor glm-r
US7579000B2 (en) 2002-05-01 2009-08-25 Bayer Schering Pharma Ag Tissue factor targeted antibodies as anticoagulants
AU2003225256B2 (en) 2002-05-01 2009-06-04 Bayer Schering Pharma Aktiengesellschaft Novel tissue factor targeted thrombomodulin fusion proteins as anticoagulants
EP1671642A1 (en) 2004-12-15 2006-06-21 Universite D'angers Compositions comprising (ant)agonists of oncostatin M (OSM), IL-31 and IFN-gamma for modulating keratinocyte migration and functions via a receptor containing OSMRbeta as a subunit, and applications thereof.
WO2006081573A2 (en) 2005-01-28 2006-08-03 Zymogenetics, Inc. Homogeneous preparations of il-31
EP1856539B1 (en) 2005-02-14 2015-10-21 ZymoGenetics, Inc. Methods of predicting therapeutic response in atopic dermatitis to il-31 antagonists
MX2007009718A (es) 2005-02-14 2007-09-26 Zymogenetics Inc Metodos para tratar trastornos cutaneos utilizando un antagonista il-31ra.
EP2301969B1 (en) 2005-05-06 2015-12-23 ZymoGenetics, Inc. IL-31 monoclonal antibodies and methods of use
EP2001906A2 (en) 2006-01-10 2008-12-17 Zymogenetics, Inc. Methods of treating pain and inflammation in neuronal tissue using il-31ra and osmrb antagonists
PE20080333A1 (es) 2006-06-08 2008-06-15 Chugai Pharmaceutical Co Ltd Agentes para prevenir o tratar enfermedades inflamatorias

Also Published As

Publication number Publication date
ES2339843T3 (es) 2010-05-26
US8017738B2 (en) 2011-09-13
EP2135953B1 (en) 2014-04-23
PT1188830E (pt) 2010-04-09
US8362223B2 (en) 2013-01-29
US20180002396A1 (en) 2018-01-04
JP2016000042A (ja) 2016-01-07
EP1188830B1 (en) 2010-01-20
US20100016552A1 (en) 2010-01-21
EP2325316B8 (en) 2017-04-19
US8017731B2 (en) 2011-09-13
ATE455852T1 (de) 2010-02-15
JP2012147784A (ja) 2012-08-09
JP2007111051A (ja) 2007-05-10
JP5634674B2 (ja) 2014-12-03
US20030125520A1 (en) 2003-07-03
DK1188830T3 (da) 2010-04-26
JP2018033461A (ja) 2018-03-08
EP2325316B1 (en) 2016-09-07
JP2014168462A (ja) 2014-09-18
DE60043728D1 (de) 2010-03-11
US20130115620A1 (en) 2013-05-09
JP2009137978A (ja) 2009-06-25
JP2020036596A (ja) 2020-03-12
US7482440B2 (en) 2009-01-27
US20100240145A1 (en) 2010-09-23
EP2135953A1 (en) 2009-12-23
EP1188830A1 (en) 2002-03-20
EP2325316A1 (en) 2011-05-25
EP1188830A4 (en) 2005-02-09
AU4952400A (en) 2000-12-28
WO2000075314A1 (fr) 2000-12-14
US20100240096A1 (en) 2010-09-23

Similar Documents

Publication Publication Date Title
CY1115582T1 (el) Νεα πρωτεϊνη υποδοχεα αιμοποιητινης, nr10
Delli-Bovi et al. Processing, secretion, and biological properties of a novel growth factor of the fibroblast growth factor family with oncogenic potential
NO995044D0 (no) Osteoprotegerinbindende proteiner og reseptorer
DK203489A (da) Anti-t-celle receptor determinanter til diagnosticering og behandling af autoimmune sygdomme
EA200901129A1 (ru) Нуклеиновые кислоты и полипептиды нового рецептора
Barnier et al. Mouse 89 kD heat shock protein: two polypeptides with distinct developmental regulation
PT917571E (pt) Gene relacionado com agouti
DK0861261T3 (da) Nukleotid- og proteinsekvenser af hvirveldyrs-Delta-gener og fremgangsmåder baseret derpå
BR9710665A (pt) Compostos que promovem o desenvolvimento do tecido
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
ATE366814T1 (de) Gl50 moleküle, sowie verwendungen derselben
ATE418563T1 (de) Nik proteine, nukleinsäure sowie verfahren
AR023482A1 (es) Acidos nucleicos que codifican polipeptidos quimericos cd40/cd4ol, metodos para su produccion y usos de los mismos
JP2007534613A (ja) レラキシンスーパーファミリーペプチド類似体
Inui et al. Dipeptide transporters
DK0877803T3 (da) OB-proteinreceptor og relaterede sammensætninger og fremgangsmåder
PT1007559E (pt) Celulas geneticamente modificadas que expressam as proteinas morfogeneticas do osso
PT914419E (pt) Ratinhos transgenicos capazes de expressar o factor de inibicao de leucemia
DE69328060D1 (de) Angiotensin-II Typ-1 Rezeptor und dessen Herstellung
Too et al. Prolactin induces expression of FGF-2 and a novel FGF-responsive NonO/p54nrb-related mRNA in rat lymphoma cells
US7589063B2 (en) Molecules which promote hematopoiesis
DE3751646D1 (de) Rekombinantes Produkt
ATE260339T1 (de) Antikörper gegen menschliches restrictin
NZ547877A (en) Angiogenesis affecting polypeptides, proteins, and compositions, and methods of use thereof
Westermark et al. Platelet derived Growth Factor and its Role in Mitogenesis and Transformation B. Westermark*, C.-H. Heldin+* Dept. of Pathology University Hospital S-751 85 Uppsala